CN101809012A - 作为血管生成抑制剂的螺取代化合物 - Google Patents
作为血管生成抑制剂的螺取代化合物 Download PDFInfo
- Publication number
- CN101809012A CN101809012A CN200880007358A CN200880007358A CN101809012A CN 101809012 A CN101809012 A CN 101809012A CN 200880007358 A CN200880007358 A CN 200880007358A CN 200880007358 A CN200880007358 A CN 200880007358A CN 101809012 A CN101809012 A CN 101809012A
- Authority
- CN
- China
- Prior art keywords
- methyl
- oxygen base
- base
- low
- base oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Abstract
Description
制备例化合物 | 激酶 | I C50(nM) |
Al3818 | FGFR1(h) | 20 |
Al3818 | Flt1(h) | 4 |
Al3818 | Flt4(h) | 1 |
Al3818 | KDR(h) | 45 |
Claims (13)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610147579.3A CN105837559B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
CN201310454104.5A CN103467454B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
CN201310454117.2A CN103483319B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89469207P | 2007-03-14 | 2007-03-14 | |
US60/894,692 | 2007-03-14 | ||
US94169807P | 2007-06-04 | 2007-06-04 | |
US60/941,698 | 2007-06-04 | ||
US12/036,244 US8148532B2 (en) | 2007-03-14 | 2008-02-23 | Spiro substituted compounds as angiogenesis inhibitors |
US12/036,244 | 2008-02-23 | ||
PCT/US2008/054816 WO2008112407A1 (en) | 2007-03-14 | 2008-02-24 | Spiro substituted compounds as angiogenesis inhibitors |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610147579.3A Division CN105837559B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
CN201310454104.5A Division CN103467454B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
CN201310454117.2A Division CN103483319B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101809012A true CN101809012A (zh) | 2010-08-18 |
CN101809012B CN101809012B (zh) | 2013-11-27 |
Family
ID=39759893
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310454104.5A Active CN103467454B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
CN201310454117.2A Active CN103483319B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
CN200880007358XA Active CN101809012B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
CN201610147579.3A Active CN105837559B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310454104.5A Active CN103467454B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
CN201310454117.2A Active CN103483319B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610147579.3A Active CN105837559B (zh) | 2007-03-14 | 2008-02-24 | 作为血管生成抑制剂的螺取代化合物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8148532B2 (zh) |
EP (1) | EP2125776B1 (zh) |
JP (1) | JP5522371B2 (zh) |
KR (1) | KR101514469B1 (zh) |
CN (4) | CN103467454B (zh) |
AU (1) | AU2008226666B2 (zh) |
BR (1) | BRPI0805826B8 (zh) |
CA (1) | CA2709220C (zh) |
DK (1) | DK2125776T3 (zh) |
ES (1) | ES2643619T3 (zh) |
IL (1) | IL200934A0 (zh) |
MX (1) | MX2009008953A (zh) |
NZ (1) | NZ579389A (zh) |
PL (1) | PL2125776T3 (zh) |
PT (1) | PT2125776T (zh) |
WO (1) | WO2008112407A1 (zh) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105153028A (zh) * | 2010-09-12 | 2015-12-16 | 南京爱德程医药科技有限公司 | 作为c-Met激酶抑制剂的化合物 |
CN105213394A (zh) * | 2014-06-06 | 2016-01-06 | 正大天晴药业集团股份有限公司 | 具有抗肿瘤活性的喹啉衍生物 |
CN105311029A (zh) * | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
CN105311030A (zh) * | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
WO2016091167A1 (zh) * | 2014-12-09 | 2016-06-16 | 正大天晴药业集团股份有限公司 | 抗肺鳞癌的喹啉衍生物 |
WO2016091168A1 (zh) * | 2014-12-09 | 2016-06-16 | 正大天晴药业集团股份有限公司 | 抗非小细胞肺癌的喹啉衍生物 |
WO2017118401A1 (zh) * | 2016-01-08 | 2017-07-13 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 |
CN106999484A (zh) * | 2014-12-09 | 2017-08-01 | 正大天晴药业集团股份有限公司 | 治疗非小细胞肺癌的喹啉衍生物 |
CN107771078A (zh) * | 2015-05-04 | 2018-03-06 | 爱德程医药有限公司 | 用于制备抗癌剂1‑((4‑(4‑氟‑2‑甲基‑1h‑吲哚‑5‑基氧基)‑6‑甲氧基喹啉‑7‑基氧基)甲基)环丙胺、其结晶形式和其盐的方法 |
CN107915751A (zh) * | 2013-02-20 | 2018-04-17 | 卡拉制药公司 | 治疗性化合物和其用途 |
US10112945B2 (en) | 2014-07-14 | 2018-10-30 | Advenchen Pharmaceuticals, Nanjing Ltd. | Fused quinoline compunds as PI3K, mTOR inhibitors |
CN108864050A (zh) * | 2018-07-25 | 2018-11-23 | 上海博璞诺科技发展有限公司 | 一种合成安罗替尼及其盐酸盐的方法 |
CN109422731A (zh) * | 2017-08-24 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 氘代喹啉衍生物 |
WO2019140937A1 (zh) * | 2018-01-22 | 2019-07-25 | 上海市第一人民医院 | 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤的应用 |
WO2019154273A1 (zh) * | 2018-02-11 | 2019-08-15 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
CN110357856A (zh) * | 2018-04-09 | 2019-10-22 | 新发药业有限公司 | 一种盐酸安罗替尼中间体及盐酸安罗替尼的制备方法 |
CN110483392A (zh) * | 2018-05-14 | 2019-11-22 | 上海海和药物研究开发有限公司 | 合成n-保护的喹啉-7-基氧基甲基环丙基胺衍生物的方法及合成中间体 |
WO2019223672A1 (zh) * | 2018-05-22 | 2019-11-28 | 正大天晴药业集团股份有限公司 | 用于治疗非小细胞肺癌的喹啉衍生物 |
WO2019233458A1 (zh) * | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | Vegfr抑制剂及其制备方法和应用 |
CN110577546A (zh) * | 2018-06-08 | 2019-12-17 | 江苏威凯尔医药科技有限公司 | Vegfr抑制剂及其制备方法和应用 |
WO2020001406A1 (zh) * | 2018-06-25 | 2020-01-02 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的晶习及其结晶粉末的制备方法 |
US10730878B2 (en) | 2015-07-11 | 2020-08-04 | Advenchen Pharmaceuticals, LLC | Fused quinoline compounds as PI3K/mTOR inhibitors |
US10736887B2 (en) | 2016-04-15 | 2020-08-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treating gastric cancer |
CN111643502A (zh) * | 2019-03-04 | 2020-09-11 | 正大天晴药业集团股份有限公司 | 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌 |
CN111643503A (zh) * | 2019-03-04 | 2020-09-11 | 正大天晴药业集团股份有限公司 | 用于治疗非小细胞肺癌的喹啉衍生物 |
CN111840289A (zh) * | 2019-04-28 | 2020-10-30 | 正大天晴药业集团股份有限公司 | 用于治疗骨巨细胞瘤的喹啉类化合物或其药学上可接受的盐 |
CN112912373A (zh) * | 2020-03-18 | 2021-06-04 | 北京康辰药业股份有限公司 | 血管生成抑制剂、其制备方法和应用 |
WO2021143928A1 (zh) * | 2020-01-19 | 2021-07-22 | 正大天晴药业集团股份有限公司 | 用于治疗类风湿性关节炎的喹啉衍生物 |
CN113262223A (zh) * | 2020-02-17 | 2021-08-17 | 上海交通大学医学院 | 安罗替尼及其药学上可接受的盐在制备治疗多发性骨髓瘤药物中的应用 |
WO2021184958A1 (zh) * | 2020-03-18 | 2021-09-23 | 北京康辰药业股份有限公司 | 血管生成抑制剂、其制备方法和应用 |
US11279676B2 (en) | 2018-03-02 | 2022-03-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystalline of compound as c-Met kinase inhibitor and preparation method therefor and use thereof |
US11419862B2 (en) | 2018-03-14 | 2022-08-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of nasopharyngeal carcinoma |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
US8211911B2 (en) | 2008-08-19 | 2012-07-03 | Guoqing Paul Chen | Compounds as kinase inhibitors |
EP2532657B9 (en) * | 2008-10-14 | 2017-04-19 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
CA2752421C (en) * | 2009-03-21 | 2013-08-06 | Ning Xi | Amino ester derivatives, salts thereof and methods of use |
CN102344438B (zh) * | 2010-08-01 | 2014-02-19 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶及其制备方法 |
CN103664890B (zh) * | 2010-08-01 | 2016-10-05 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶及制备方法 |
CA2829131C (en) | 2011-03-04 | 2018-11-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Amino-quinolines as kinase inhibitors |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
US9695108B2 (en) | 2012-08-23 | 2017-07-04 | Georgetown University | Compounds and methods of use thereof for treating tumors |
AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
JP2016506917A (ja) * | 2013-01-18 | 2016-03-07 | アドヴェンチェン ファーマスーティカルズ,エルエルシー | 抗腫瘍剤6−(7−((1−アミノシクロプロピル)メトキシ)−6−メトキシキノリン−4−イルオキシ)−n−メチル−1−ナフトアミドおよびその結晶を調製するプロセス |
JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
US9695184B2 (en) * | 2013-02-15 | 2017-07-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
AU2014220300B2 (en) | 2013-02-21 | 2016-10-13 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
WO2017035114A1 (en) | 2015-08-25 | 2017-03-02 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as cb-1 inverse agonists |
BR112018006873A2 (pt) | 2015-10-05 | 2018-11-06 | The Trustees Of Columbia University In The City Of New York | ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias |
CN107778288B (zh) * | 2016-08-26 | 2020-07-28 | 正大天晴药业集团股份有限公司 | 一种喹啉衍生物的杂质及其制备方法和用途 |
CN107778290B (zh) * | 2016-08-30 | 2020-07-24 | 正大天晴药业集团股份有限公司 | 一种喹啉衍生物的杂质及其制备方法 |
CN110650741A (zh) * | 2017-05-26 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 用于治疗结直肠癌的喹啉衍生物 |
WO2019052520A1 (zh) | 2017-09-15 | 2019-03-21 | 正大天晴药业集团股份有限公司 | 用于治疗神经内分泌肿瘤的喹啉衍生物 |
CA3093612A1 (en) | 2018-03-14 | 2019-09-19 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of nasopharyngeal carcinoma |
CN111757737B (zh) * | 2018-03-14 | 2022-07-08 | 正大天晴药业集团股份有限公司 | 用于治疗三阴性乳腺癌的喹啉衍生物 |
CA3106055A1 (en) | 2018-07-18 | 2020-01-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Therapeutic combination of quinoline derivative and antibody |
CN115850237A (zh) * | 2018-07-24 | 2023-03-28 | 正大天晴药业集团股份有限公司 | 一种吲哚衍生物的合成方法 |
WO2020029918A1 (zh) * | 2018-08-06 | 2020-02-13 | 正大天晴药业集团股份有限公司 | 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 |
CN117085016A (zh) | 2018-09-18 | 2023-11-21 | 正大天晴药业集团股份有限公司 | 用于治疗小细胞肺癌的喹啉衍生物 |
WO2020057403A1 (zh) * | 2018-09-18 | 2020-03-26 | 北京越之康泰生物医药科技有限公司 | 吲哚衍生物及其在医药上的应用 |
CN116444489A (zh) * | 2018-12-29 | 2023-07-18 | 正大天晴药业集团股份有限公司 | 喹啉衍生物及其制备方法和用途 |
CN109748904A (zh) | 2019-01-31 | 2019-05-14 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
CN111617243B (zh) * | 2019-02-28 | 2023-12-19 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
CN111714498A (zh) * | 2019-03-20 | 2020-09-29 | 正大天晴药业集团股份有限公司 | 用于治疗卵巢癌的喹啉衍生物 |
CA3137204A1 (en) | 2019-04-19 | 2020-10-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline compound or pharmaceutically acceptable salt thereof for treating ewing's sarcoma |
EP3967310A4 (en) | 2019-05-10 | 2023-01-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | QUINOLINE DERIVATIVE USED IN SOFT TISSUE SARCOMBINATION THERAPY |
EP3967309A4 (en) | 2019-05-10 | 2023-01-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | COMBINATION THERAPY WITH QUINOLINE DERIVATIVE AND ANTIBODIES FOR SOFT TISSUE SARCOMA |
US20220267444A1 (en) | 2019-08-02 | 2022-08-25 | CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. | Anti-pd-1 antibody and medical use thereof |
BR112022002013A2 (pt) | 2019-08-02 | 2022-03-29 | Akeso Pharmaceuticals Inc | Anticorpo biespecífico anti-ctla4/anti-pd-1 e uso do mesmo |
US20220378776A1 (en) | 2019-11-04 | 2022-12-01 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Drug combination of quinoline derivative and pd-1 monoclonal antibody |
CN111888358A (zh) * | 2020-08-24 | 2020-11-06 | 天津济坤医药科技有限公司 | 安罗替尼在制备用于治疗肝纤维化疾病的药物中的应用 |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
AU7340096A (en) | 1995-11-07 | 1997-05-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
EP1154774B1 (en) | 1999-02-10 | 2005-06-22 | AstraZeneca AB | Quinazoline derivatives as angiogenesis inhibitors |
KR100589032B1 (ko) | 2000-10-20 | 2006-06-14 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
EP1548008A4 (en) * | 2002-08-23 | 2008-08-06 | Kirin Pharma Kk | COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION |
US7129252B2 (en) | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
MXPA06002256A (es) | 2003-08-29 | 2006-05-17 | Pfizer | Naftaleno carboxamidas y sus derivados utiles como agentes anti-angiogenicos. |
MXPA06005024A (es) * | 2003-11-06 | 2006-07-06 | Pfizer Prod Inc | Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer. |
UA82577C2 (en) * | 2003-12-23 | 2008-04-25 | Пфайзер Инк. | Quinoline derivatives |
CN1933839A (zh) | 2004-01-23 | 2007-03-21 | 安进公司 | 化合物和使用方法 |
US7626030B2 (en) | 2004-01-23 | 2009-12-01 | Amgen Inc. | Compounds and methods of use |
TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
WO2005097137A2 (en) | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Advanced quinazoline based protein kinase inhibitors |
US20080268460A1 (en) | 2004-05-20 | 2008-10-30 | Wyeth | Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases |
KR100735639B1 (ko) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
US8163923B2 (en) * | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
-
2008
- 2008-02-23 US US12/036,244 patent/US8148532B2/en active Active
- 2008-02-24 BR BRPI0805826A patent/BRPI0805826B8/pt active IP Right Grant
- 2008-02-24 CN CN201310454104.5A patent/CN103467454B/zh active Active
- 2008-02-24 CA CA2709220A patent/CA2709220C/en active Active
- 2008-02-24 PL PL08730589T patent/PL2125776T3/pl unknown
- 2008-02-24 CN CN201310454117.2A patent/CN103483319B/zh active Active
- 2008-02-24 MX MX2009008953A patent/MX2009008953A/es active IP Right Grant
- 2008-02-24 KR KR1020097016377A patent/KR101514469B1/ko active IP Right Grant
- 2008-02-24 EP EP08730589.2A patent/EP2125776B1/en active Active
- 2008-02-24 WO PCT/US2008/054816 patent/WO2008112407A1/en active Application Filing
- 2008-02-24 DK DK08730589.2T patent/DK2125776T3/en active
- 2008-02-24 NZ NZ579389A patent/NZ579389A/en unknown
- 2008-02-24 CN CN200880007358XA patent/CN101809012B/zh active Active
- 2008-02-24 PT PT87305892T patent/PT2125776T/pt unknown
- 2008-02-24 JP JP2009553672A patent/JP5522371B2/ja active Active
- 2008-02-24 CN CN201610147579.3A patent/CN105837559B/zh active Active
- 2008-02-24 ES ES08730589.2T patent/ES2643619T3/es active Active
- 2008-02-24 AU AU2008226666A patent/AU2008226666B2/en active Active
-
2009
- 2009-09-14 IL IL200934A patent/IL200934A0/en active IP Right Grant
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105153028B (zh) * | 2010-09-12 | 2019-03-26 | 南京爱德程医药科技有限公司 | 作为c-Met激酶抑制剂的化合物 |
CN105153028A (zh) * | 2010-09-12 | 2015-12-16 | 南京爱德程医药科技有限公司 | 作为c-Met激酶抑制剂的化合物 |
CN107915751A (zh) * | 2013-02-20 | 2018-04-17 | 卡拉制药公司 | 治疗性化合物和其用途 |
CN105311029A (zh) * | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
US10251876B2 (en) | 2014-06-06 | 2019-04-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Method for treating tumour, pharmaceutical composition and medicinal kit |
CN111035639A (zh) * | 2014-06-06 | 2020-04-21 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物 |
CN106413712A (zh) * | 2014-06-06 | 2017-02-15 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 |
CN106456626A (zh) * | 2014-06-06 | 2017-02-22 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物 |
CN106456625A (zh) * | 2014-06-06 | 2017-02-22 | 正大天晴药业集团股份有限公司 | 包含喹啉衍生物或其盐的药物组合物及其制备方法 |
CN112076192A (zh) * | 2014-06-06 | 2020-12-15 | 正大天晴药业集团股份有限公司 | 包含喹啉衍生物或其盐的药物组合物及其制备方法 |
CN105213394A (zh) * | 2014-06-06 | 2016-01-06 | 正大天晴药业集团股份有限公司 | 具有抗肿瘤活性的喹啉衍生物 |
US9968597B2 (en) | 2014-06-06 | 2018-05-15 | Advenchen Laboratories Nanjing Ltd | Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same |
CN111012784A (zh) * | 2014-06-06 | 2020-04-17 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物 |
CN111035640A (zh) * | 2014-06-06 | 2020-04-21 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗甲状腺癌的方法和用途 |
CN111012784B (zh) * | 2014-06-06 | 2022-02-18 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物 |
CN105213394B (zh) * | 2014-06-06 | 2019-04-09 | 正大天晴药业集团股份有限公司 | 具有抗肿瘤活性的喹啉衍生物 |
CN111035639B (zh) * | 2014-06-06 | 2022-02-18 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物 |
CN105311030A (zh) * | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
CN111035640B (zh) * | 2014-06-06 | 2024-03-19 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗甲状腺癌的方法和用途 |
US10183017B2 (en) | 2014-06-06 | 2019-01-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same |
US10112945B2 (en) | 2014-07-14 | 2018-10-30 | Advenchen Pharmaceuticals, Nanjing Ltd. | Fused quinoline compunds as PI3K, mTOR inhibitors |
CN107001326B (zh) * | 2014-12-09 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 抗非小细胞肺癌的喹啉衍生物 |
US10307412B2 (en) | 2014-12-09 | 2019-06-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative against non-small cell lung cancer |
WO2016091167A1 (zh) * | 2014-12-09 | 2016-06-16 | 正大天晴药业集团股份有限公司 | 抗肺鳞癌的喹啉衍生物 |
WO2016091168A1 (zh) * | 2014-12-09 | 2016-06-16 | 正大天晴药业集团股份有限公司 | 抗非小细胞肺癌的喹啉衍生物 |
US10888559B2 (en) | 2014-12-09 | 2021-01-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivatives for non-small cell lung cancer |
CN106999484A (zh) * | 2014-12-09 | 2017-08-01 | 正大天晴药业集团股份有限公司 | 治疗非小细胞肺癌的喹啉衍生物 |
CN107001326A (zh) * | 2014-12-09 | 2017-08-01 | 正大天晴药业集团股份有限公司 | 抗非小细胞肺癌的喹啉衍生物 |
CN106999485A (zh) * | 2014-12-09 | 2017-08-01 | 正大天晴药业集团股份有限公司 | 抗肺鳞癌的喹啉衍生物 |
CN106999485B (zh) * | 2014-12-09 | 2020-04-14 | 正大天晴药业集团股份有限公司 | 抗肺鳞癌的喹啉衍生物 |
US10544125B2 (en) | 2015-05-04 | 2020-01-28 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
US10100034B2 (en) | 2015-05-04 | 2018-10-16 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
CN110292580B (zh) * | 2015-05-04 | 2023-08-04 | 杭州爱德程医药科技有限公司 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN107771078A (zh) * | 2015-05-04 | 2018-03-06 | 爱德程医药有限公司 | 用于制备抗癌剂1‑((4‑(4‑氟‑2‑甲基‑1h‑吲哚‑5‑基氧基)‑6‑甲氧基喹啉‑7‑基氧基)甲基)环丙胺、其结晶形式和其盐的方法 |
CN110294741B (zh) * | 2015-05-04 | 2021-09-03 | 杭州爱德程医药科技有限公司 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN110292579A (zh) * | 2015-05-04 | 2019-10-01 | 杭州爱德程医药科技有限公司 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN110294741A (zh) * | 2015-05-04 | 2019-10-01 | 杭州爱德程医药科技有限公司 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN110292580A (zh) * | 2015-05-04 | 2019-10-01 | 杭州爱德程医药科技有限公司 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN110172057A (zh) * | 2015-05-04 | 2019-08-27 | 杭州爱德程医药科技有限公司 | 喹啉衍生物的盐及其结晶形式 |
CN107771078B (zh) * | 2015-05-04 | 2021-11-02 | 杭州爱德程医药科技有限公司 | 用于制备抗癌剂1-((4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)甲基)环丙胺、其结晶形式和其盐的方法 |
US10730878B2 (en) | 2015-07-11 | 2020-08-04 | Advenchen Pharmaceuticals, LLC | Fused quinoline compounds as PI3K/mTOR inhibitors |
WO2017118401A1 (zh) * | 2016-01-08 | 2017-07-13 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 |
US10561647B2 (en) | 2016-01-08 | 2020-02-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof |
US10736887B2 (en) | 2016-04-15 | 2020-08-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treating gastric cancer |
CN109422731A (zh) * | 2017-08-24 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 氘代喹啉衍生物 |
WO2019140937A1 (zh) * | 2018-01-22 | 2019-07-25 | 上海市第一人民医院 | 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤的应用 |
CN111630045A (zh) * | 2018-02-11 | 2020-09-04 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
WO2019154273A1 (zh) * | 2018-02-11 | 2019-08-15 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
US11279676B2 (en) | 2018-03-02 | 2022-03-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystalline of compound as c-Met kinase inhibitor and preparation method therefor and use thereof |
US11419862B2 (en) | 2018-03-14 | 2022-08-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of nasopharyngeal carcinoma |
CN110357856A (zh) * | 2018-04-09 | 2019-10-22 | 新发药业有限公司 | 一种盐酸安罗替尼中间体及盐酸安罗替尼的制备方法 |
CN110483392A (zh) * | 2018-05-14 | 2019-11-22 | 上海海和药物研究开发有限公司 | 合成n-保护的喹啉-7-基氧基甲基环丙基胺衍生物的方法及合成中间体 |
CN112105361A (zh) * | 2018-05-22 | 2020-12-18 | 正大天晴药业集团股份有限公司 | 用于治疗非小细胞肺癌的喹啉衍生物 |
WO2019223672A1 (zh) * | 2018-05-22 | 2019-11-28 | 正大天晴药业集团股份有限公司 | 用于治疗非小细胞肺癌的喹啉衍生物 |
CN110577546B (zh) * | 2018-06-08 | 2021-09-07 | 江苏威凯尔医药科技有限公司 | Vegfr抑制剂及其制备方法和应用 |
CN110577546A (zh) * | 2018-06-08 | 2019-12-17 | 江苏威凯尔医药科技有限公司 | Vegfr抑制剂及其制备方法和应用 |
WO2019233458A1 (zh) * | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | Vegfr抑制剂及其制备方法和应用 |
CN112368273A (zh) * | 2018-06-25 | 2021-02-12 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的晶习及其结晶粉末的制备方法 |
US11731955B2 (en) | 2018-06-25 | 2023-08-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal habit of quinoline derivative and preparation method for crystalline powder thereof |
WO2020001406A1 (zh) * | 2018-06-25 | 2020-01-02 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的晶习及其结晶粉末的制备方法 |
CN108864050A (zh) * | 2018-07-25 | 2018-11-23 | 上海博璞诺科技发展有限公司 | 一种合成安罗替尼及其盐酸盐的方法 |
CN108864050B (zh) * | 2018-07-25 | 2019-12-10 | 上海博璞诺科技发展有限公司 | 一种合成安罗替尼及其盐酸盐的方法 |
CN111643503A (zh) * | 2019-03-04 | 2020-09-11 | 正大天晴药业集团股份有限公司 | 用于治疗非小细胞肺癌的喹啉衍生物 |
CN111643502A (zh) * | 2019-03-04 | 2020-09-11 | 正大天晴药业集团股份有限公司 | 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌 |
CN111840289A (zh) * | 2019-04-28 | 2020-10-30 | 正大天晴药业集团股份有限公司 | 用于治疗骨巨细胞瘤的喹啉类化合物或其药学上可接受的盐 |
CN114929225A (zh) * | 2020-01-19 | 2022-08-19 | 正大天晴药业集团股份有限公司 | 用于治疗类风湿性关节炎的喹啉衍生物 |
WO2021143928A1 (zh) * | 2020-01-19 | 2021-07-22 | 正大天晴药业集团股份有限公司 | 用于治疗类风湿性关节炎的喹啉衍生物 |
CN113262223A (zh) * | 2020-02-17 | 2021-08-17 | 上海交通大学医学院 | 安罗替尼及其药学上可接受的盐在制备治疗多发性骨髓瘤药物中的应用 |
WO2021184958A1 (zh) * | 2020-03-18 | 2021-09-23 | 北京康辰药业股份有限公司 | 血管生成抑制剂、其制备方法和应用 |
CN112912373A (zh) * | 2020-03-18 | 2021-06-04 | 北京康辰药业股份有限公司 | 血管生成抑制剂、其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20090129985A (ko) | 2009-12-17 |
WO2008112407A1 (en) | 2008-09-18 |
CN101809012B (zh) | 2013-11-27 |
CN103467454A (zh) | 2013-12-25 |
IL200934A0 (en) | 2010-05-17 |
EP2125776A4 (en) | 2011-06-22 |
CN105837559B (zh) | 2019-11-29 |
CN103483319B (zh) | 2015-10-14 |
MX2009008953A (es) | 2009-12-18 |
CN103467454B (zh) | 2016-05-04 |
CA2709220A1 (en) | 2008-09-18 |
JP2010521473A (ja) | 2010-06-24 |
KR101514469B1 (ko) | 2015-04-22 |
EP2125776B1 (en) | 2017-07-05 |
US8148532B2 (en) | 2012-04-03 |
NZ579389A (en) | 2012-04-27 |
PL2125776T3 (pl) | 2017-12-29 |
PT2125776T (pt) | 2017-10-04 |
ES2643619T3 (es) | 2017-11-23 |
BRPI0805826B8 (pt) | 2021-05-25 |
US20080227811A1 (en) | 2008-09-18 |
BRPI0805826A2 (pt) | 2011-08-30 |
AU2008226666B2 (en) | 2013-10-03 |
CA2709220C (en) | 2016-07-19 |
CN103483319A (zh) | 2014-01-01 |
JP5522371B2 (ja) | 2014-06-18 |
BRPI0805826B1 (pt) | 2021-02-09 |
EP2125776A1 (en) | 2009-12-02 |
DK2125776T3 (en) | 2017-10-23 |
CN105837559A (zh) | 2016-08-10 |
AU2008226666A1 (en) | 2008-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101809012B (zh) | 作为血管生成抑制剂的螺取代化合物 | |
CN101558055B (zh) | 作为血管生成抑制剂的螺取代化合物 | |
CN102159078B (zh) | 作为激酶抑制剂的化合物 | |
CN103328447B (zh) | 作为c-Met激酶抑制剂的化合物 | |
CN101316590B (zh) | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 | |
CN101431894B (zh) | 螺环化合物和应用方法 | |
CN105120869A (zh) | 眼部病症的治疗 | |
TW201041875A (en) | JAK kinase modulating compounds and methods of use thereof | |
CN105722840A (zh) | 作为PI3K、mTOR抑制剂的稠合喹啉化合物 | |
KR20060009893A (ko) | Src 억제제와 조합된 항혈관형성제를 포함하는 치료제및 이것의 치료 용도 | |
CN1854130B (zh) | 喹唑啉衍生物、及其制法和药物组合物与用途 | |
CN107428762A (zh) | 酞嗪酮衍生物、其制备方法及用途 | |
CN101423513B (zh) | 胺基嘧啶衍生物、及其制法和药物组合物与用途 | |
CN101696183B (zh) | (z)-2-苯基-3-(吡咯-2-基)-丙烯腈衍生物及其盐、组合物以及制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 210000 building 302, building A, incubator of medicine and biology, Nanjing hi tech Development Zone, Nanjing, Jiangsu Applicant after: Advenchen Laboratories, LLC Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Applicant after: Advenchen Laboratories LLC Address before: 210000 building 302, building A, incubator of medicine and biology, Nanjing hi tech Development Zone, Nanjing, Jiangsu Applicant before: Advenchen Laboratories, LLC Applicant before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Applicant before: Advenchen Laboratories LLC |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200423 Address after: Room 302, block a, pharmaceutical biological incubator building, entrepreneurship center, Nanjing high tech Development Zone, Jiangsu Province Co-patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: Guoqing Chen Address before: 210000 building 302, building A, incubator of medicine and biology, Nanjing hi tech Development Zone, Nanjing, Jiangsu Co-patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Guoqing Chen Co-patentee before: ADVENCHEN LAB LLC |